Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 9

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 9
---
 4,993,000 
  
    CASH FLOWS FROM FINANCING ACTIVITIES 

    Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options 
     (12,769,000) 
     (1,157,000)
  
    Proceeds from exercise of stock options 
     125,000  
     521,000 
  
    Payment of debt issuance costs 
     -  
     (100,000)
  
    NET CASH USED IN FINANCING ACTIVITIES 
     (12,644,000) 
     (736,000)
  
    NET CHANGE IN CASH AND CASH EQUIVALENTS 
     5,716,000  
     (3,117,000)
  
    CASH AND CASH EQUIVALENTS, beginning of period 
     47,247,000  
     74,085,000 
  
    CASH, CASH EQUIVALENTS, end of period 
    $52,963,000  
    $70,968,000 
  
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: 

    Cash paid for income taxes 
    $38,000  
    $- 
  
    Cash paid for interest 
    $12,180,000  
    $10,316,000 
  
    SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: 

    Purchase of property, plant and equipment included in accounts payable and accrued expenses 
    $130,000  
    $44,000 
  
    Change in right-of-use assets for operating lease obligations assumptions 
    $-  
    $377,000 

The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements

6

HARROW,
INC.

NOTES
TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For
the Three and Six Months Ended June 30, 2025 and 2024

NOTE
1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Company
and Background

Harrow,
Inc. (together with its consolidated subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Harrow”)
is a leading provider of ophthalmic disease management solutions in North America